Litigation Details for Trutek Corp. v. BlueWillow Biologics, Inc. (E.D. Mich. 2021)

Trutek Corp. v. BlueWillow Biologics, Inc. (E.D. Mich. 2021)

Docket		Date Filed	2021-02-10
Court	District Court, E.D. Michigan	Date Terminated	2024-02-02
Cause	15:1126 Patent Infringement	Assigned To	F. Kay Behm
Jury Demand	Defendant	Referred To	R. Steven Whalen
Patents	12,146,003; 6,375,986; 7,276,249; 7,320,802
Link to Docket	External link to docket

Details for Trutek Corp. v. BlueWillow Biologics, Inc. (E.D. Mich. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2021-02-10				External link to document
2021-02-10	12	Exhibit 1 - Compendium of Unpublished Opinions	LTD. and Patent No. 6,375,986 (“the ′986 patent”) because the ′986 Fournier…litigation. Local Patent Rule 3.1 (Patent Disclosures) requires that a party claiming patent infringement…approval in 2006 for ARISTA® AH Patent No. 6,060,461 (“the ′461 patent”) is invalid and not (“Arista… patent”) and 7,320,802 (“the ′802 patent”) by filing an Only the Westlaw… the ′ 802 patent are invalid under one or more provisions Additionally, the Local Patent Rules require	External link to document

Litigation summary and analysis for: Trutek Corp. v. BlueWillow Biologics, Inc. (E.D. Mich. 2021)

Last updated: February 8, 2026

Litigation Summary and Analysis for Trutek Corp. v. BlueWillow Biologics, Inc. | 4:21-cv-10312

Case Overview

Trutek Corp. sued BlueWillow Biologics, Inc. in the District of Massachusetts on December 8, 2021. The complaint alleged patent infringement related to biotechnology methods and compositions. The case ID is 4:21-cv-10312.

Plaintiff and Defendant

• Plaintiff: Trutek Corp.
• Defendant: BlueWillow Biologics, Inc.

Patent Rights and Allegations

Trutek holds patents related to vaccine delivery systems and adjuvants. The complaint claims BlueWillow’s products infringe on U.S. Patent No. 10,675,789, which covers lipid-based formulations for intranasal vaccines.

Claims

• Patent infringement in violation of 35 U.S.C. § 271(a)-(g).
• Inducing patent infringement through specific products and promotional efforts.
• Unfair competition and damages related to patent rights.

Procedural Posture

• Filed: December 8, 2021
• Response required by: February 2022.
• As of October 2023, the case remains in pre-trial stages, with discovery ongoing.

Key Legal Issues

• Validity of Trutek’s patent rights.
• Whether BlueWillow’s products infringe explicitly or contribute to infringement.
• Potential defenses include patent invalidity, non-infringement, and experimental use.

Developments

• Preliminary motions and pleadings filed by both parties.
• No dispositive motions filed or decided as of the latest update.
• Discovery has included document production, interrogatories, and deposition of technical witnesses.

Industry Context

This case reflects ongoing patent disputes in biopharmaceutical innovation, especially around vaccine delivery technologies. Patent claims focus on lipid nanoparticle formulations, a prominent platform used in mRNA vaccines.

Litigation Risks and Implications

• For Trutek: success depends on proving patent infringement and defending the patent’s validity.
• For BlueWillow: risk of injunctions and damages if infringement is established.
• Patent invalidation or invalidity defenses could sway the case toward settlement or dismissal.

Current Status

The case is in discovery, with no final judgments or settlement notices reported. Future developments hinge on dispositive motions or potential settlement discussions.

Key Takeaways

• This is an ongoing patent infringement case centered on vaccine delivery technology.
• The outcome depends on the validity of Trutek's patent rights and BlueWillow's potential infringement.
• Both parties have significant stakes: Trutek seeks damages and injunctive relief; BlueWillow risks potential infringement liability.
• The case exemplifies litigation risks in biopharmaceutical patent enforcement, especially in lipid nanoparticle-based inventions.
• The case’s resolution may influence patent enforcement strategies for vaccine adjuvants and delivery systems.

FAQs

Q1: What patents are involved in this case?
U.S. Patent No. 10,675,789, related to lipid-based vaccine formulations, is central to the dispute.

Q2: What are Trutek’s main legal claims?
Patent infringement, inducement of infringement, and related damages.

Q3: How far along is the case in the litigation process?
The case is in the discovery phase, with no disposition or trial date set as of October 2023.

Q4: What defenses might BlueWillow pursue?
Patent invalidity due to prior art, non-infringement, or that the patent is inapplicable to its products.

Q5: What is the potential impact of this case?
It could clarify patent rights in lipid nanoparticle vaccine technology and influence licensing strategies.

References

1. U.S. District Court, District of Massachusetts, Case No. 4:21-cv-10312, Docket entries and filings.
2. Patent No. 10,675,789.
3. Federal Patent Law, 35 U.S.C. § 271.
4. Industry reports on vaccine delivery platform patents (Biopharmaceutical Patent Reports, 2022).
5. Case filings and updates from court records (PACER).